Sierra Oncology, Inc. (SRRA)
| Market Cap | 176.54M |
| Revenue (ttm) | 100,000 |
| Net Income (ttm) | -110.34M |
| Shares Out | 10.44M |
| EPS (ttm) | -11.91 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $16.06 |
| Previous Close | $15.95 |
| Change ($) | 0.11 |
| Change (%) | 0.69% |
| Day's Open | 16.00 |
| Day's Range | 15.66 - 16.17 |
| Day's Volume | 12,342 |
| 52-Week Range | 8.88 - 16.70 |
- Ms. Thomson brings extensive strategic, transactional and intellectual property experience as Sierra prepares for potential transition into a commercial company -
Sierra Oncology, Inc (SRRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Sierra Oncology, Inc. (SRRA) Nick Glover on Q4 2019 Results - Earnings Call Transcript
Sierra Oncology (SRRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.
Sierra Oncology has been struggling lately, but the selling pressure may be coming to an end soon.
About SRRA
Sierra Oncology researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis. The company is also advancing SRA737, an orally bioavailable small molecule inhibitor Checkpoint kinase 1 is being investigated in two Phase 1/2 clinical trials; and SRA141, an orally bioavailable small molecule i... [Read more...]
| Industry Biotechnology | IPO Date Jul 16, 2015 |
| CEO Stephen Dilly | Employees 71 |
| Stock Exchange NASDAQ | Ticker Symbol SRRA |
Analyst Forecasts
According to 4 analysts, the average rating for SRRA stock is "Strong Buy." The 12-month stock price forecast is 27.75, which is an increase of 72.79% from the latest price.